Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
449 Leser
Artikel bewerten:
(2)

Spectra Medical Devices: Spectra Medical, XL Precision Technologies Announce Rebrand as Elevaris Medical Devices

Legacy of Trust and Expertise Ushers in New Era of Precision Medical Device Development and Manufacturing Capabilities

BOSTON, Jan. 28, 2025 /PRNewswire/ -- Spectra Medical Devices (Spectra) and XL Precision Technologies (XLPT) announced today their newly combined brand presence as Elevaris Medical Devices, a world-class Contract Development and Manufacturing Organization (CDMO) leveraging a proven legacy of excellence to usher in a new era of precision medical device development and manufacturing capabilities.

The Spectra acquisition of XLPT, announced in September 2024 by healthcare technology and services investor QHP Capital, brought together the companies' complementary strengths in servicing medical device manufacturers from large-scale Original Equipment Manufacturers (OEMs) to start-ups. Spectra has long been highly regarded for the expansive engineering and manufacturing capabilities and expert technical customer support it provides OEMs. XLPT is widely admired for its specialty manufacturing expertise in precision micro-components, complex tubular components, and sub-assemblies.

Today's announcement marks the formal evolution to a unified brand that equally honors the rich history of each company and embodies their combined commitment to providing their deep knowledge, unparalleled collaborative approach, and extensive precision manufacturing capabilities to customers worldwide. The decision to establish a new company name and brand identity reflects the promise to apply the best practices and strengths of the individual brands while also emphasizing a singular commitment to elevating customer outcomes to the next level.

"The acquisition late last year brought together two long-trusted companies with highly complementary capabilities," Richard Zrebiec, CEO of Elevaris Medical Devices, said. "Today, as we complete integration, we believe operating under one brand demonstrates our combined commitment to our customers' success."

As the newly branded company, Elevaris Medical Devices will serve medical device companies in an unrivaled capacity. The unified team of engineering, design, and development experts is highly invested in applying its deep knowledge and product perspective to provide value-driven design, development and production solutions that support the success of customer projects.

"From concept, to design and development, through manufacturing, we are uniquely qualified to support our customers in their quest to develop next-generation medical devices that enable the future of healthcare and improve global health," Zrebiec said. "Elevaris Medical Devices has the capability to be the preferred partner to drive a new era of precision medical device development and manufacturing."

About Elevaris Medical Devices:

Elevaris Medical Devices is a Contract Development and Manufacturing Organization (CDMO) for industry-leading, multi-national healthcare companies, global Original Equipment Manufacturers (OEMs), and emerging technology companies. It is one of the world's leading manufacturers of made-to-spec procedural needles and specializes in the manufacture of precision micro-components, complex tubular components, and sub-assemblies for the medical device industry. The company also distributes a wide range of complementary pharmaceutical products, surgical instruments, and medical supplies.

Elevaris Medical Devices has more than 300 employees across its locations in North America, the UK, and South Korea. For more information, visit elevarismedical.com.

Elevaris Medical Devices logo

Video - https://mma.prnewswire.com/media/2607088/Elevaris_animated_logo_video.mp4
Photo - https://mma.prnewswire.com/media/2607087/ElevarisLogoTag_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/spectra-medical-xl-precision-technologies-announce-rebrand-as-elevaris-medical-devices-302361383.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.